CN Patent

CN101365703A — 杂烷基连接的嘧啶衍生物

Assigned to SBio Pte Ltd · Expires 2009-02-11 · 17y expired

What this patent protects

本发明涉及可作为抗增生剂的嘧啶化合物。更具体地说，本发明涉及杂烷基连接并经取代的嘧啶化合物、其制备方法、含有这些化合物的药物组合物和这些化合物在治疗增生性疾病中的用途。这些化合物可作为药物治疗包括肿瘤和癌症等多种增生性疾病以及激酶相关其它疾病或病症。

USPTO Abstract

本发明涉及可作为抗增生剂的嘧啶化合物。更具体地说，本发明涉及杂烷基连接并经取代的嘧啶化合物、其制备方法、含有这些化合物的药物组合物和这些化合物在治疗增生性疾病中的用途。这些化合物可作为药物治疗包括肿瘤和癌症等多种增生性疾病以及激酶相关其它疾病或病症。

Drugs covered by this patent

pacritinib-citrate (PACRITINIB CITRATE)

Patent Metadata

Patent number: CN101365703A
Jurisdiction: CN
Classification: —
Expires: 2009-02-11
Drug substance claim: No
Drug product claim: No
Assignee: SBio Pte Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.